JAMA Editors' Summary From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, RSV Vaccine to Prevent Hospitalizations in Older Adults, and more
14 snips
Sep 1, 2025 Gregory Curfman, Executive Editor at JAMA, and Robert O. Bonow, JAMA Cardiology Editor, tackle pressing advancements in cardiac care. They discuss the benefits of remote ECG monitoring for atrial fibrillation detection and the safety of discontinuing anticoagulants post-ablation. The duo also dives into the comparative effectiveness of semaglutide and tirzepatide in heart failure treatment. Lastly, they underscore the significance of bivalent RSV vaccination for older adults, while highlighting the need for greater female representation in cardiovascular trials.
AI Snips
Chapters
Transcript
Episode notes
Short Patch Monitoring Shows Limited Stroke Benefit
- Two-week patch ECG screening only modestly increased asymptomatic AF detection compared with usual care.
- It did not reduce stroke over 2.5 years, so routine patch screening likely won't prevent strokes.
When To Consider Stopping Anticoagulation
- Consider stopping anticoagulation after documented AF-free year following successful catheter ablation.
- Ensure continuous monitoring to confirm absence of recurrent AF before discontinuation.
Pump Benefits Concentrated At Very Low BP
- Microaxial pump benefit in infarct-related cardiogenic shock appears concentrated in patients with very low systolic BP.
- A cutoff near 82 mmHg identified a subgroup with markedly lower mortality using the pump.